Effect of enzalutamide on time to first skeletal-related event, pain, and quality of life in men with castration-resistant prostate cancer: results from the randomised, phase 3 AFFIRM trial.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

In the AFFIRM trial of patients with metastatic castration-resistant prostate cancer after progression with docetaxel treatment, enzalutamide significantly increased overall survival compared with placebo. Here we present the prospectively defined analyses of some secondary endpoints, including occurrence of skeletal-related events, measures of pain control, and patient-reported health-related quality of life (HRQoL).

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): Lancet Oncol.

Title: The Lancet. Oncology

ISSN (Electronic): 1474-5488

ISSN (Print): 1470-2045

Publication date (Electronic): Sep 2014

Volume: 15

Issue: 10

Affiliations

[1 ] Institut Gustave Roussy, University of Paris Sud, Villejuif, France. Electronic address: karim.fizazi@gustaveroussy.fr.

[2 ] Memorial Sloan-Kettering Cancer Center and Weill Cornell Medical College, New York, NY, USA.

[3 ] Charité Berlin, Berlin, Germany.

[4 ] Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC, USA.

[5 ] San Camillo and Forlanini Hospitals, Rome, Italy.

[6 ] Department of Medical Social Sciences, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA.

[7 ] Medivation, San Francisco, CA, USA.

[8 ] Royal Marsden Hospital and the Institute of Cancer Research, Sutton, UK.

Article

Publisher Item ID: S1470-2045(14)70303-1

DOI: 10.1016/S1470-2045(14)70303-1

PubMed ID: 25104109

SO-VID: 2def14bb-c9a1-4403-bda6-90cbd7ecad33

History

Data availability:

Comments

Comment on this article

scite_

Cited by 62

See all cited by

- Version 1